MA31006B1 - Composition a liberation prolongee et procede de production correspondant - Google Patents

Composition a liberation prolongee et procede de production correspondant

Info

Publication number
MA31006B1
MA31006B1 MA32010A MA32010A MA31006B1 MA 31006 B1 MA31006 B1 MA 31006B1 MA 32010 A MA32010 A MA 32010A MA 32010 A MA32010 A MA 32010A MA 31006 B1 MA31006 B1 MA 31006B1
Authority
MA
Morocco
Prior art keywords
physiologically active
weight
producing
same
lactic acid
Prior art date
Application number
MA32010A
Other languages
English (en)
Inventor
Tomomichi Futo
Kazuhiro Saito
Tetsuo Hoshino
Masuhisa Hori
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39015849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31006(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA31006B1 publication Critical patent/MA31006B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

LA PRÉSENTE INVENTION SE RAPPORTE À DES COMPOSITIONS À LIBÉRATION PROLONGÉE COMPRENANT UN PEPTIDE PHYSIOLOGIQUEMENT ACTIF HYDROSOLUBLE DISPERSÉ DE MANIÈRE SENSIBLEMENT UNIFORME DANS UNE MICROCAPSULE COMPOSÉE D'UN POLYMÈRE D'ACIDE LACTIQUE OU D'UN SEL DE CELUI-CI, LA SUBSTANCE PHYSIOLOGIQUEMENT ACTIVE ÉTANT PRÉSENTE EN UNE QUANTITÉ COMPRISE ENTRE 15 ET 35% POIDS/POIDS PAR RAPPORT AU POIDS TOTAL DES MICROCAPSULES, LE POIDS MOLÉCULAIRE MOYEN EN POIDS (MW) DU POLYMÈRE D'ACIDE LACTIQUE ÉTANT COMPRIS ENTRE 11000 ET 27000 ENVIRON. CES COMPOSITIONS SE CARACTÉRISENT PAR UNE FORTE TENEUR EN SUBSTANCE PHYSIOLOGIQUEMENT ACTIVE, PAR LA SUPPRESSION DE LA LIBÉRATION EXCESSIVE INITIALE DANS LE JOUR SUIVANT L'ADMINISTRATION ET PAR UNE LIBÉRATION PROLONGÉE STABLE DE MÉDICAMENT SUR UNE LONGUE PÉRIODE. CETTE INVENTION CONCERNE ÉGALEMENT UN PROCÉDÉ DE PRODUCTION CORRESPONDANT.
MA32010A 2006-12-18 2009-06-17 Composition a liberation prolongee et procede de production correspondant MA31006B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87536406P 2006-12-18 2006-12-18
US91740107P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
MA31006B1 true MA31006B1 (fr) 2009-12-01

Family

ID=39015849

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32010A MA31006B1 (fr) 2006-12-18 2009-06-17 Composition a liberation prolongee et procede de production correspondant

Country Status (27)

Country Link
US (3) US8921326B2 (fr)
EP (1) EP2094246B1 (fr)
JP (2) JP4564098B2 (fr)
KR (1) KR101522035B1 (fr)
CN (1) CN101563068B (fr)
AR (1) AR064381A1 (fr)
AU (1) AU2007335406B2 (fr)
BR (1) BRPI0720582B1 (fr)
CA (1) CA2671670C (fr)
CL (1) CL2007003658A1 (fr)
CO (1) CO6180498A2 (fr)
CR (1) CR10867A (fr)
DO (1) DOP2009000144A (fr)
EA (1) EA016176B1 (fr)
EC (1) ECSP099439A (fr)
ES (1) ES2791698T3 (fr)
GE (1) GEP20125597B (fr)
IL (1) IL198845A (fr)
MA (1) MA31006B1 (fr)
MX (1) MX2009006653A (fr)
MY (1) MY148370A (fr)
NO (1) NO347209B1 (fr)
NZ (1) NZ577281A (fr)
PE (1) PE20081842A1 (fr)
TN (1) TN2009000197A1 (fr)
TW (1) TWI481424B (fr)
WO (1) WO2008075762A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI481424B (zh) 2006-12-18 2015-04-21 Takeda Pharmaceutical 緩釋性組成物及其製法
CN107412725A (zh) * 2009-12-22 2017-12-01 武田药品工业株式会社 缓释制剂
US20130210742A1 (en) * 2010-06-25 2013-08-15 Takeda Pharmaceutical Company Limited Sustained-release formulation
US20150087624A1 (en) * 2012-04-24 2015-03-26 Osaka University Method for producing an aqueous dispersion of drug nanoparticles and use thereof
KR101558083B1 (ko) * 2014-04-07 2015-10-07 에스케이케미칼주식회사 약물함유 고분자미립구 제조방법
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
EP3687503A1 (fr) * 2017-09-26 2020-08-05 Nanomi B.V. Procédé de préparation de microparticules par une technique de double émulsion
KR101936040B1 (ko) * 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
ES2944511T3 (es) 2019-03-26 2023-06-21 Novel Pharma Inc Derivado de GnRH que se une a ácido graso de acción prolongada y composición farmacéutica que comprende el mismo
EP3998065A4 (fr) * 2019-07-12 2023-07-12 G2Gbio, Inc. Formulation à longue durée d'action contenant de la rivastigmine et son procédé de préparation
CN116270491A (zh) * 2023-03-30 2023-06-23 北京博恩特药业有限公司 一种醋酸亮丙瑞林缓释微球及其制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) * 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) * 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) * 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4258063A (en) * 1978-06-23 1981-03-24 Henkel Corporation Self-emulsifying cosmetic base
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US5366734A (en) * 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) * 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en) * 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
CA1256638A (fr) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymere, et sa production
ATE61935T1 (de) 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
CA2040141C (fr) * 1990-04-13 2002-05-14 Minoru Yamada Polymeres biodegradables a haute densite moleculaire production et utilisation desdits polymeres
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
EP0582459B1 (fr) * 1992-08-07 1998-01-07 Takeda Chemical Industries, Ltd. Production de microcapsules de médicaments solubles dans l'eau
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
DE4342092B4 (de) 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
US5594091A (en) * 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
JPH07273447A (ja) 1994-03-29 1995-10-20 Sumitomo Kinzoku Ceramics:Kk セラミック回路基板及びその製造方法
US5763513A (en) * 1994-05-19 1998-06-09 Mitsui Toatsu Chemicals, Inc. L-lactic acid polymer composition, molded product and film
FR2736508B1 (fr) 1995-07-13 1997-09-19 Francais Prod Ind Cfpi Nouvelle forme solide de stockage et de commercialisation pour compositions phytosanitaires et moyens pour sa preparation
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
CA2192773C (fr) * 1995-12-15 2008-09-23 Hiroaki Okada Obtention d'une preparation a liberation prolongee pour injection
CA2192782C (fr) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production de microsphere
EP0839525B1 (fr) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Préparation à libération retardée
JPH10273447A (ja) 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
AU5678398A (en) 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2316273A1 (fr) * 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Compositions a liberation controlee, leur procede de fabrication et leur utilisation
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
DE69914460T2 (de) 1998-03-04 2004-10-28 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter wirkstoffabgabe für aii antagonisten, ihre herstellung und verwendung
US6114495A (en) * 1998-04-01 2000-09-05 Cargill Incorporated Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6270802B1 (en) * 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
CA2355186C (fr) 1998-12-15 2008-03-18 Takeda Pharmaceutical Company Limited Procede de production d'un polymere
CN1361685A (zh) 1999-07-15 2002-07-31 武田药品工业株式会社 缓释组合物、其制备方法和用途
AU6510400A (en) 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
DK1310517T4 (da) 2000-08-07 2011-01-17 Wako Pure Chem Ind Ltd Mælkesyrepolymer og fremgangsmåde til fremstilling af denne
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
WO2002043766A1 (fr) 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Compositions medicinales et leur procede de preparation
WO2002047722A1 (fr) 2000-12-15 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
TWI332407B (en) 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
US20050064039A1 (en) * 2001-12-26 2005-03-24 Tomomichi Futo Novel microsphere and method for production thereof
DK1532985T3 (en) 2002-06-25 2016-12-05 Takeda Pharmaceuticals Co PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE
US6803708B2 (en) * 2002-08-22 2004-10-12 Cdream Display Corporation Barrier metal layer for a carbon nanotube flat panel display
CA2819769C (fr) 2003-07-18 2016-06-28 Oakwood Laboratories, L.L.C. Methode pour empecher la perte de poids moleculaire des polymeres, la formation d'impuretes et la gelification dans les composes polymeriques
US8900636B2 (en) 2003-07-23 2014-12-02 Evonik Corporation Controlled release compositions
WO2005030806A2 (fr) * 2003-09-24 2005-04-07 Montana State University Anticorps monoclonaux de norovirus et peptides
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
CN101890167B (zh) 2004-10-01 2017-03-01 拉姆斯科股份有限公司 可方便植入的缓释药物组合物
PL1824460T3 (pl) 2004-11-10 2015-09-30 Tolmar Therapeutics Inc Stabilizowany polimerowy układ dostarczania
TWI481424B (zh) 2006-12-18 2015-04-21 Takeda Pharmaceutical 緩釋性組成物及其製法

Also Published As

Publication number Publication date
AU2007335406B2 (en) 2012-09-13
DOP2009000144A (es) 2009-07-30
BRPI0720582A2 (pt) 2014-02-04
IL198845A (en) 2015-07-30
KR20090094272A (ko) 2009-09-04
MX2009006653A (es) 2009-07-02
WO2008075762A1 (fr) 2008-06-26
CL2007003658A1 (es) 2008-05-09
KR101522035B1 (ko) 2015-05-20
NO20092662L (no) 2009-09-07
JP2010222371A (ja) 2010-10-07
IL198845A0 (en) 2010-02-17
CA2671670A1 (fr) 2008-06-26
CA2671670C (fr) 2015-02-10
TW200833376A (en) 2008-08-16
TWI481424B (zh) 2015-04-21
EA200970600A1 (ru) 2009-12-30
JP4564098B2 (ja) 2010-10-20
US9617303B2 (en) 2017-04-11
CR10867A (es) 2009-07-30
US8921326B2 (en) 2014-12-30
BRPI0720582B1 (pt) 2021-08-24
PE20081842A1 (es) 2009-01-19
US20170165204A1 (en) 2017-06-15
US20150080322A1 (en) 2015-03-19
NO347209B1 (no) 2023-07-03
EA016176B1 (ru) 2012-02-28
CN101563068A (zh) 2009-10-21
TN2009000197A1 (en) 2010-10-18
ES2791698T3 (es) 2020-11-05
EP2094246B1 (fr) 2020-04-01
CO6180498A2 (es) 2010-07-19
NZ577281A (en) 2011-12-22
JP5258844B2 (ja) 2013-08-07
AR064381A1 (es) 2009-04-01
JP2010513225A (ja) 2010-04-30
CN101563068B (zh) 2013-03-20
MY148370A (en) 2013-04-15
GEP20125597B (en) 2012-08-10
AU2007335406A1 (en) 2008-06-26
US9713595B2 (en) 2017-07-25
ECSP099439A (es) 2009-07-31
EP2094246A1 (fr) 2009-09-02
US20110135741A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
MA31006B1 (fr) Composition a liberation prolongee et procede de production correspondant
CA2473201C (fr) Composition pharmaceutique orodispersible d'agomelatine
MA31797B1 (fr) Compositions pharmaceutiques
US12226397B2 (en) Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
CH644758A5 (fr) Composition aqueuse stable a base de peroxyde de benzoyle.
EP4277593A1 (fr) Methode cosmetique et composition a base de fructooligosaccharides a chaine courte et d'un amidon natif
FR2918376A1 (fr) Compositions liquides ou pateuses destinees a l'apport en elements essentiels a la synthese et a la constitution des proteoglycanes, notamment pour le traitement de la degradation du cartilage
CA2985013A1 (fr) Association d'acide lipoique et de taurine en tant qu'agent osmoprotecteur
EP2254567B1 (fr) N-acetyl-taurinate de zinc pour son utilisation dans une méthode de prévention et/ou de traitement des maladies avec accumulation de lipofuscine
FR2938188A1 (fr) Composition cosmetique topique apte a regenerer la peau
CA2985014C (fr) Composition ophtalmique comprenant de l'acide lipoique et un polymere muco-mimetique
WO2023198519A1 (fr) Extraits de fleurs de crocus sativus, compositions les comprenant et leurs utilisations dans les soins buccaux
FR3069776A1 (fr) Compositions cosmetiques pour les soins de la peau
WO2007093747A2 (fr) Utilisation du tesaglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
FR3036284A1 (fr) Acide lipoique en tant qu'agent osmoprotecteur
FR3127881B1 (fr) Composition pour le soin des matières kératineuses
FR3046727A3 (fr) Association d'acide lipoique et de taurine en tant qu'agent osmoprotecteur
UA97125C2 (ru) Композиция продолжительного высвобождения и способ ее получения
WO2022200334A1 (fr) Composition nutraceutique comprenant de l'inuline pour le traitement et la prevention des troubles oculaires ou le desequilibre de la microbiote intestinal
WO2007068577A1 (fr) Utilisation du naveglitazar pour la préparation d'une composition pharmaceutique destinée au traitement des affections dermatologiques
WO2003080020A1 (fr) Composition thermoreversible destinee au traitement des hyposialies et asialies
JP2008100948A (ja) 硫化水素および／または硫化水素塩を含有する神経細胞分化促進剤およびその方法
EP1406663A2 (fr) Composition a base de polymeres vegetaux immobilisant des actifs
WO2007093746A2 (fr) Utilisation du muraglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
FR3020571A1 (fr) Co-granules de gomme de xanthane et de gomme d'acacia